Oridonin inhibits inflammation of epithelial cells via dual-targeting of CD31 Keap1 to ameliorate acute lung injury.

ABSTRACT:

Introdcution

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are major causes of COVID-19 mortality. However, drug delivery to lung tissues is impeded by endothelial cell barriers, limiting the efficacy of existing treatments. A prompt and aggressive treatment strategy is therefore necessary.

Methods

We assessed the ability of anti-CD31-ORI-NPs to penetrate endothelial cell barriers and specifically accumulate in lung tissues using an animal model. We also compared the efficacy of anti-CD31-ORI-NPs to that of free oridonin in ameliorating acute lung injury and evaluated the cytotoxicity of both treatments on endothelial cells.

Results

Compared to free ORI, the amount of anti-CD31-ORI-NPs accumulated in lung tissues increase at least three times.

SUBMITTER: Zhao Y 

PROVIDER: S-EPMC10116055 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature